Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.2% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s share price traded down 2.2% on Friday . The stock traded as low as $1,171.20 and last traded at $1,182.2430. 2,106,481 shares changed hands during mid-day trading, a decline of 32% from the average session volume of 3,111,201 shares. The stock had previously closed at $1,209.00.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. regulator approved Lilly’s once-daily oral weight-loss pill, Foundayo (orforglipron), giving the company an important commercial foothold in Europe and expanding its obesity-treatment opportunity. Eli Lilly Just Scored Europe’s First Weight Loss Pill Approval
• Positive Sentiment: Foundayo generated $98 million in second-quarter sales following its April launch, providing an early indication that Lilly’s oral GLP-1 franchise could complement Mounjaro and Zepbound. LLY’s Foundayo Posts $98M in Q2 Sales
• Positive Sentiment: Lilly is expanding its obesity pipeline with a new Phase 1 macupatide study in Japan. The trial adds geographic reach and another potential growth driver, although it remains at an early development stage. Lilly Expands Obesity Pipeline With Fresh Macupatide Trial in Japan
• Neutral Sentiment: Analysts continue to view LLY as a fundamental powerhouse nearing a technical buy point, but the stock’s elevated valuation and imperfect chart setup may be limiting new buying. Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains
• Negative Sentiment: Recent insider sales, including a 2,000-share sale by Chief Accounting Officer Donald Zakrowski, may be contributing to caution after Lilly’s substantial earnings-driven advance. Donald Zakrowski Sells 2,000 Shares of Eli Lilly
• Negative Sentiment: Competitive pressure remains a concern as Novo Nordisk argues the obesity market will support multiple differentiated treatments rather than a single dominant winner. That view could temper expectations for Lilly’s market share and long-term pricing power. Novo CEO Says Obesity Market Won’t Be Winner-Take-All

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on LLY shares. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Truist Financial boosted their target price on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Jefferies Financial Group increased their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Royal Bank Of Canada raised their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 8th. Finally, Citigroup lifted their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,292.18.

Eli Lilly and Company Trading Down 2.2%

The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $1.11 trillion, a PE ratio of 39.67, a price-to-earnings-growth ratio of 1.44 and a beta of 0.51. The stock’s fifty day moving average price is $1,169.84 and its two-hundred day moving average price is $1,051.85.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.Eli Lilly and Company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 36.33 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 23.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Farther Finance Advisors LLC raised its holdings in shares of Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after acquiring an additional 7,338 shares during the last quarter. Iams Wealth Management LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $754,000. Amundi boosted its stake in shares of Eli Lilly and Company by 9.9% in the first quarter. Amundi now owns 5,055,025 shares of the company’s stock worth $4,649,464,000 after acquiring an additional 454,549 shares during the last quarter. Generali Investments Management Co LLC boosted its stake in shares of Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after acquiring an additional 1,521 shares during the last quarter. Finally, May Hill Capital LLC increased its position in shares of Eli Lilly and Company by 131.6% during the fourth quarter. May Hill Capital LLC now owns 3,170 shares of the company’s stock worth $3,408,000 after purchasing an additional 1,801 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.